Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$567.39
11.172.01%
À la fermeture: -
$567.39
0.000.00%
Après les heures de négociation: Oct 31, 4:18 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Thermo Fisher Scientific Inc a un objectif de cours consensus de $624.96, basé sur les évaluations des 27 analystes. Le plus élevé est de $680 attribué par Redburn Atlantic le octobre 14, 2024, et le plus bas est de $535 attribué par Raymond James le juillet 24, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Argus Research, Morgan Stanley et UBS le octobre 29, 2025, octobre 28, 2025 et octobre 23, 2025. Avec un objectif de cours moyen de $618.67 entre Argus Research, Morgan Stanley et UBS, il y a une variation implicite de 9.04% upside pour Thermo Fisher Scientific Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Argus Research
Morgan Stanley
UBS
TD Cowen
Wells Fargo
1calculé à partir des notes des analystes
Notes d'analystes pour Thermo Fisher Scientific
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/29/2025 | 7.51% | Argus Research | $580 → $610 | Maintains | Buy | |||
10/28/2025 | 15.62% | Morgan Stanley | $560 → $656 | Maintains | Overweight | |||
10/23/2025 | 3.98% | UBS | $500 → $590 | Maintains | Neutral | |||
10/23/2025 | 15.26% | TD Cowen | $612 → $654 | Maintains | Buy | |||
10/23/2025 | 11.92% | Wells Fargo | $565 → $635 | Maintains | Overweight | |||
10/23/2025 | 10.15% | Barclays | $585 → $625 | Maintains | Overweight | |||
10/23/2025 | 2.22% | Citigroup | $500 → $580 | Maintains | Neutral | |||
10/22/2025 | 2.22% | Leerink Partners | $545 → $580 | Maintains | Outperform | |||
10/09/2025 | 14.56% | JP Morgan | $600 → $650 | Maintains | Overweight | |||
10/07/2025 | 3.98% | Evercore ISI Group | $525 → $590 | Maintains | Outperform | |||
10/02/2025 | 3.1% | Barclays | $550 → $585 | Maintains | Overweight | |||
09/11/2025 | -3.06% | Barclays | $490 → $550 | Upgrade | Equal-Weight → Overweight | |||
08/19/2025 | — | William Blair | — | Initiates | → Outperform | |||
07/24/2025 | -11.88% | UBS | $460 → $500 | Maintains | Neutral | |||
07/24/2025 | -5.71% | Raymond James | $525 → $535 | Reiterates | Outperform → Outperform | |||
07/24/2025 | -0.42% | Wells Fargo | $570 → $565 | Maintains | Overweight | |||
07/24/2025 | -13.64% | Barclays | $450 → $490 | Maintains | Equal-Weight | |||
07/24/2025 | -0.07% | Baird | $553 → $567 | Maintains | Outperform | |||
07/18/2025 | -2.54% | Baird | $573 → $553 | Maintains | Outperform | |||
07/11/2025 | 3.98% | Scotiabank | → $590 | Upgrade | Sector Perform → Sector Outperform | |||
07/09/2025 | -18.93% | UBS | $500 → $460 | Downgrade | Buy → Neutral | |||
07/08/2025 | -15.4% | Evercore ISI Group | $500 → $480 | Maintains | Outperform | |||
06/24/2025 | -20.69% | Barclays | $475 → $450 | Maintains | Equal-Weight | |||
04/29/2025 | -17.16% | Argus Research | $620 → $470 | Maintains | Buy | |||
04/25/2025 | 6.63% | Scotiabank | $650 → $605 | Maintains | Sector Perform | |||
04/24/2025 | 12.27% | RBC Capital | $651 → $637 | Maintains | Outperform | |||
04/24/2025 | -11.88% | UBS | $715 → $500 | Maintains | Buy | |||
04/24/2025 | 9.27% | Stifel | $665 → $620 | Maintains | Buy | |||
04/24/2025 | -11.88% | Evercore ISI Group | $585 → $500 | Maintains | Outperform | |||
04/24/2025 | 0.46% | Wells Fargo | $580 → $570 | Maintains | Overweight | |||
04/24/2025 | 0.99% | Baird | $603 → $573 | Maintains | Outperform | |||
04/17/2025 | 2.22% | Wells Fargo | $680 → $580 | Maintains | Overweight | |||
04/10/2025 | -16.28% | Barclays | $620 → $475 | Maintains | Equal-Weight | |||
03/04/2025 | 0.46% | Citigroup | $650 → $570 | Maintains | Neutral | |||
02/03/2025 | 14.56% | Scotiabank | $605 → $650 | Maintains | Sector Perform | |||
02/03/2025 | 17.56% | Raymond James | $650 → $667 | Reiterates | Outperform → Outperform | |||
01/31/2025 | 14.56% | Citigroup | $600 → $650 | Maintains | Neutral | |||
01/31/2025 | 26.02% | UBS | $700 → $715 | Maintains | Buy | |||
01/31/2025 | 19.85% | Wells Fargo | $660 → $680 | Maintains | Overweight | |||
01/31/2025 | 19.49% | Morgan Stanley | $647 → $678 | Maintains | Overweight | |||
01/13/2025 | 14.03% | Morgan Stanley | $670 → $647 | Maintains | Overweight | |||
12/23/2024 | 6.63% | Scotiabank | → $605 | Initiates | → Sector Perform | |||
12/13/2024 | 16.32% | B of A Securities | $675 → $660 | Maintains | Buy | |||
10/24/2024 | 9.27% | Bernstein | $625 → $620 | Maintains | Market Perform | |||
10/24/2024 | 26.54% | RBC Capital | $767 → $718 | Maintains | Outperform | |||
10/24/2024 | 17.2% | Stifel | $680 → $665 | Maintains | Buy | |||
10/24/2024 | 9.27% | Evercore ISI Group | $630 → $620 | Maintains | Outperform | |||
10/24/2024 | 16.32% | Wells Fargo | $670 → $660 | Maintains | Overweight | |||
10/24/2024 | 9.62% | Baird | $632 → $622 | Maintains | Outperform | |||
10/23/2024 | 7.51% | Barclays | $620 → $610 | Maintains | Equal-Weight | |||
10/15/2024 | 9.27% | Barclays | $600 → $620 | Maintains | Equal-Weight | |||
10/14/2024 | 19.85% | Redburn Atlantic | — | → $680 | Initiates | → Buy | ||
10/01/2024 | 11.03% | Evercore ISI Group | $605 → $630 | Maintains | Outperform | |||
10/01/2024 | 19.85% | Stephens & Co. | → $680 | Initiates | → Overweight | |||
09/20/2024 | 18.08% | JP Morgan | $650 → $670 | Maintains | Overweight | |||
09/20/2024 | 19.85% | Stifel | $615 → $680 | Maintains | Buy | |||
09/20/2024 | 35.18% | RBC Capital | $767 → $767 | Reiterates | Outperform → Outperform | |||
09/20/2024 | 19.85% | Morgan Stanley | $655 → $680 | Maintains | Overweight | |||
09/16/2024 | 18.97% | B of A Securities | $600 → $675 | Maintains | Buy | |||
08/27/2024 | 18.08% | Wells Fargo | → $670 | Initiates | → Overweight | |||
07/25/2024 | 15.97% | TD Cowen | $648 → $658 | Maintains | Buy | |||
07/25/2024 | 16.32% | Raymond James | $650 → $660 | Maintains | Outperform | |||
07/25/2024 | 17.03% | RBC Capital | $660 → $664 | Maintains | Outperform | |||
07/25/2024 | 8.39% | Stifel | $600 → $615 | Maintains | Buy | |||
07/25/2024 | 11.39% | Baird | $620 → $632 | Maintains | Outperform | |||
07/02/2024 | 5.75% | Evercore ISI Group | $615 → $600 | Maintains | Outperform | |||
06/28/2024 | 5.75% | Barclays | $615 → $600 | Maintains | Equal-Weight | |||
06/03/2024 | 14.56% | Jefferies | $600 → $650 | Assumes | Hold → Buy | |||
04/30/2024 | 18.08% | HSBC | $660 → $670 | Maintains | Buy | |||
04/25/2024 | 14.56% | JP Morgan | $600 → $650 | Maintains | Overweight | |||
04/25/2024 | 8.39% | Barclays | $590 → $615 | Maintains | Equal-Weight | |||
04/25/2024 | 7.51% | Deutsche Bank | $600 → $610 | Maintains | Buy | |||
04/25/2024 | 9.27% | Baird | $621 → $620 | Maintains | Outperform | |||
04/17/2024 | 16.32% | HSBC | $630 → $660 | Maintains | Buy | |||
04/10/2024 | 12.8% | Goldman Sachs | $550 → $640 | Maintains | Buy | |||
04/04/2024 | 7.51% | Evercore ISI Group | $575 → $610 | Maintains | Outperform | |||
03/18/2024 | 9.27% | Citigroup | → $620 | Reinstates | → Neutral | |||
02/01/2024 | 13.15% | RBC Capital | $592 → $642 | Maintains | Outperform | |||
02/01/2024 | 6.63% | Raymond James | $515 → $605 | Maintains | Outperform | |||
01/24/2024 | -2.18% | Barclays | $475 → $555 | Downgrade | Overweight → Equal-Weight | |||
01/08/2024 | — | Bernstein | — | Downgrade | Outperform → Market Perform | |||
12/18/2023 | 7.51% | HSBC | → $610 | Initiates | → Buy | |||
12/14/2023 | 18.08% | Baird | → $670 | Maintains | Outperform | |||
12/13/2023 | — | Wolfe Research | — | Initiates | → Outperform | |||
12/11/2023 | 1.34% | Citigroup | $530 → $575 | Maintains | Buy | |||
11/06/2023 | -3.06% | Argus Research | $540 → $550 | Maintains | Buy | |||
10/26/2023 | -7.65% | Baird | $589 → $524 | Maintains | Outperform | |||
10/26/2023 | -16.28% | Barclays | $585 → $475 | Maintains | Overweight | |||
10/26/2023 | -6.59% | Stifel | $660 → $530 | Maintains | Buy | |||
10/26/2023 | 2.05% | RBC Capital | $657 → $579 | Maintains | Outperform | |||
10/26/2023 | -6.59% | Citigroup | $625 → $530 | Maintains | Buy | |||
10/26/2023 | -9.23% | Raymond James | $580 → $515 | Maintains | Outperform | |||
10/26/2023 | -3.95% | Morgan Stanley | $600 → $545 | Maintains | Overweight | |||
10/26/2023 | — | Keybanc | — | Downgrade | Overweight → Sector Weight | |||
10/25/2023 | -11.88% | Goldman Sachs | → $500 | Maintains | Buy | |||
10/25/2023 | 1.34% | B of A Securities | → $575 | Maintains | Buy | |||
10/24/2023 | 5.75% | Morgan Stanley | $640 → $600 | Maintains | Overweight | |||
10/23/2023 | 3.81% | Baird | $625 → $589 | Maintains | Outperform | |||
10/18/2023 | 2.22% | Raymond James | $630 → $580 | Maintains | Outperform | |||
10/17/2023 | 11.03% | JP Morgan | $670 → $630 | Maintains | Overweight |
FAQ
Quel est le cours indicatif de l'action Thermo Fisher Scientific (TMO) ?
Le dernier objectif de prix pour Thermo Fisher Scientific (NYSE:TMO) a été rapporté par Argus Research le octobre 29, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $610.00 s'attendant à ce que TMO se rise dans les 12 prochains mois (un possible changement de 7.51% upside). 43 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Thermo Fisher Scientific (TMO) ?
La dernière note d'analyste pour Thermo Fisher Scientific (NYSE:TMO) a été fournie par Argus Research, et Thermo Fisher Scientific maintenu leur note buy.
Quand a eu lieu la dernière mise à niveau pour Thermo Fisher Scientific (TMO) ?
La dernière amélioration pour Thermo Fisher Scientific Inc a eu lieu le septembre 11, 2025 lorsque Barclays a augmenté leur objectif de prix à $550. Barclays avait précédemment an equal-weight pour Thermo Fisher Scientific Inc.
Quand a eu lieu la dernière dégradation pour Thermo Fisher Scientific (TMO) ?
La dernière réduction pour Thermo Fisher Scientific Inc a eu lieu le juillet 9, 2025 lorsque UBS a changé leur objectif de prix de $500 à $460 pour Thermo Fisher Scientific Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Thermo Fisher Scientific (TMO) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Thermo Fisher Scientific, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Thermo Fisher Scientific a été déposée le octobre 29, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 29, 2026.
La note d'analyste pour Thermo Fisher Scientific (TMO) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Thermo Fisher Scientific (TMO) était un maintenu avec un objectif de prix de $580.00 à $610.00. Le prix actuel de Thermo Fisher Scientific (TMO) est de $567.39, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.